Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma.

Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM.

Exp Biol Med (Maywood). 2009 Jul;234(7):726-36. doi: 10.3181/0901-MR-40. Epub 2009 May 8. Review.

PMID:
19429855
2.

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM.

Carcinogenesis. 2008 Aug;29(8):1639-47. doi: 10.1093/carcin/bgn155. Epub 2008 Jun 25.

PMID:
18579559
4.

Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.

Frau M, Biasi F, Feo F, Pascale RM.

Mol Aspects Med. 2010 Apr;31(2):179-93. doi: 10.1016/j.mam.2010.02.007. Epub 2010 Feb 20. Review.

PMID:
20176048
5.

Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.

Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM.

Cancer Res. 2008 Jun 1;68(11):4192-200. doi: 10.1158/0008-5472.CAN-07-6157.

6.

Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.

Frau M, Feo F, Pascale RM.

J Hepatol. 2013 Oct;59(4):830-41. doi: 10.1016/j.jhep.2013.04.031. Epub 2013 May 7. Review.

7.

Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.

Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F, Pascale RM.

J Hepatol. 2011 Jul;55(1):111-9. doi: 10.1016/j.jhep.2010.10.031. Epub 2010 Dec 7.

PMID:
21419759
8.

Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control.

Calvisi DF, Pinna F, Pellegrino R, Sanna V, Sini M, Daino L, Simile MM, De Miglio MR, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM.

Int J Cancer. 2008 Nov 1;123(9):2057-64. doi: 10.1002/ijc.23720.

9.

Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis.

Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G, Casabona D, Frau M, Seddaiu MA, Feo F.

Hepatology. 2002 Jun;35(6):1341-50.

PMID:
12029619
10.

Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, De Miglio MR, Tomasi ML, Sanna V, Muroni MR, Feo F, Pascale RM.

Gut. 2009 May;58(5):679-87. doi: 10.1136/gut.2008.152652. Epub 2009 Jan 9.

PMID:
19136513
11.

[Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].

Xue KX.

Ai Zheng. 2005 Jun;24(6):757-68. Review. Chinese.

PMID:
15946497
12.

Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer.

Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F.

Hepatology. 2005 Dec;42(6):1310-9.

PMID:
16317707
13.

Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression.

Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, Latte G, Calvisi DF, Seddaiu MA, Daino L, Feo CF, Brozzetti S, Solinas G, Yamashita S, Ushijima T, Feo F, Pascale RM.

Hepatology. 2012 Jul;56(1):165-75. doi: 10.1002/hep.25643. Epub 2012 Jun 5.

PMID:
22318685
14.

Molecular pathogenesis of hepatocellular carcinoma.

Wong CM, Ng IO.

Liver Int. 2008 Feb;28(2):160-74. Epub 2007 Dec 6. Review.

PMID:
18069974
15.

Molecular pathways and related target therapies in liver carcinoma.

Tommasi S, Pinto R, Pilato B, Paradiso A.

Curr Pharm Des. 2007;13(32):3279-87. Review.

PMID:
18045179
16.

Mapping a sex hormone-sensitive gene determining female resistance to liver carcinogenesis in a congenic F344.BN-Hcs4 rat.

De Miglio MR, Virdis P, Calvisi DF, Frau M, Muroni MR, Simile MM, Daino L, Careddu GM, Sanna-Passino E, Pascale RM, Feo F.

Cancer Res. 2006 Nov 1;66(21):10384-90.

17.

Molecular and functional genetics of hepatocellular carcinoma.

Yam JW, Wong CM, Ng IO.

Front Biosci (Schol Ed). 2010 Jan 1;2:117-34. Review.

PMID:
20036934
18.

Genetic and epigenetic events in human hepatocarcinogenesis.

Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M, Yamamoto M.

Int J Oncol. 2001 Jun;18(6):1271-8. Review.

PMID:
11351262
19.

Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies.

Feo F, Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi D.

Crit Rev Oncog. 2000;11(1):19-62. Review.

PMID:
10795626
20.

Cell brain: insight into hepatocarcinogenesis.

Chen Y, Kong Q.

Med Hypotheses. 2006;67(1):44-52.

PMID:
16600524

Supplemental Content

Support Center